<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CELESTONE SOLUSPAN - betamethasone acetate and betamethasone sodium phosphate injection, suspension </strong><br>REMEDYREPACK INC. <br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1">1</a><br><span class="Bold">brand of <br>betamethasone sodium phosphate <br>and betamethasone acetate Injectable Suspension USP<br>6 mg per mL</span></p>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>brand of rapid and repository injectable</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Inactive ingredients per mL: 7.1 mg dibasic sodium phosphate; 3.4 mg monobasic sodium phosphate; 0.1 mg edetate disodium; and 0.2 mg benzalkonium chloride as preservative. The pH is adjusted to between 6.8 and 7.2.</p>
<p>The formula for betamethasone sodium phosphate is C<span class="Sub">22</span>H<span class="Sub">28</span>FNa<span class="Sub">2</span>0<span class="Sub">8</span>P and it has a molecular weight of 516.40. Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-(disodium phosphate).</p>
<p>The formula for betamethasone acetate is C<span class="Sub">24</span>H<span class="Sub">31</span>FO<span class="Sub">6</span> and it has a molecular weight of 434.50. Chemically, it is 9-Fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 21-acetate.</p>
<p>The chemical structures for betamethasone sodium phosphate and betamethasone acetate are as follows:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2fb9fb11-d4ab-4c19-b5d1-c0177b3d8ef6&amp;name=MM1.jpg"></p>
<p>Betamethasone sodium phosphate is a white to practically white, odorless powder, and is hygroscopic. It is freely soluble in water and in methanol, but is practically insoluble in acetone and in chloroform.</p>
<p>Betamethasone acetate is a white to creamy white, odorless powder that sinters and resolidifies at about 165°C, and remelts at about 200°C-220°C with decomposition. It is practically insoluble in water, but freely soluble in acetone, and is soluble in alcohol and in chloroform.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract.</p>
<p>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16ß-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9.</p>
<p>Betamethasone sodium phosphate, a soluble ester, provides prompt activity, while betamethasone acetate is only slightly soluble and affords sustained activity.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>When oral therapy is not feasible, the <span class="Bold">intramuscular use</span> of CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension is indicated as follows:</p>
<p>
 
</p>
<p></p>
<p>Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions, perennial or <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis, exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
<p>
 
</p>
<p></p>
<p>Congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer, nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
<p>Hydrocortisone or cortisone is the drug of choice in primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span>. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.</p>
<p>
 
</p>
<p></p>
<p>To tide the patient over a critical period of the disease in <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
<p>
 
</p>
<p></p>
<p>Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, selected cases of secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>
 
</p>
<p></p>
<p>Trichinosis with neurologic or myocardial involvement, tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.</p>
<p>
 
</p>
<p></p>
<p>For palliative management of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
<p>
 
</p>
<p></p>
<p>Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>; <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span> or craniotomy.</p>
<p>
 
</p>
<p></p>
<p>Sympathetic ophthalmia, <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and ocular inflammatory conditions unresponsive to topical corticosteroids.</p>
<p>
 
</p>
<p></p>
<p>To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
<p>
 
</p>
<p></p>
<p>Berylliosis, fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy, idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>, symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
<p><span class="Bold">Rheumatic Disorders</span> As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>; acute rheumatic carditis; <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>; <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy). For the treatment of <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p>The <span class="Bold">intra-articular or soft tissue administration </span>of CELESTONE SOLUSPAN Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>, acute and subacute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, acute nonspecific <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>, <span class="product-label-link" type="condition" conceptid="4249170" conceptname="Epicondylitis">epicondylitis</span>, <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span> of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</p>
<p>The<span class="Bold"> intralesional administration </span>of CELESTONE SOLUSPAN Injectable Suspension is indicated for <span class="product-label-link" type="condition" conceptid="141933" conceptname="Alopecia areata">alopecia areata</span>; <span class="product-label-link" type="condition" conceptid="4066824" conceptname="Discoid lupus erythematosus">discoid lupus erythematosus</span>; keloids; localized hypertrophic, infiltrated, inflammatory lesions of <span class="product-label-link" type="condition" conceptid="4277253" conceptname="Granuloma annulare">granuloma annulare</span>, <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, lichen simplex chronicus (<span class="product-label-link" type="condition" conceptid="4148920" conceptname="Neurodermatitis">neurodermatitis</span>), and psoriatic plaques; necrobiosis lipoidica diabeticorum.</p>
<p>CELESTONE SOLUSPAN Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension is contraindicated in patients who are hypersensitive to any components of this product.</p>
<p>Intramuscular corticosteroid preparations are contraindicated for <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension should not be administered intravenously.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>).</p>
<p>In patients on corticosteroid therapy subjected to any unusual stress, hydrocortisone or cortisone is the drug of choice as a supplement during and after the event.</p>
<p>
 
</p>
<p></p>
<p>Average and large doses of corticosteroids can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients.</p>
<p>
 
</p>
<p></p>
<p>Corticosteroids can produce reversible hypothalamic pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.</p>
<p>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</p>
<p>
 
</p>
<p></p>
<p>Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than are healthy individuals. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>
 
</p>
<p></p>
<p>Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see <span class="Bold"><a href="#P_DI_AB">PRECAUTIONS, Drug Interactions, Amphotericin B Injection and Potassium-Depleting Agents</a></span> section).</p>
<p>
 
</p>
<p></p>
<p>Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by <span class="Italics">Amoeba, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis,</span> and<span class="Italics"> Toxoplasma.</span></p>
<p>It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>.</p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>.</p>
<p>
 
</p>
<p></p>
<p>The use of corticosteroids in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted</span>. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, eg, for Addison's disease.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Chickenpox</span> and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span>, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> develops, treatment with antiviral agents should be considered.</p>
<p>
 
</p>
<p></p>
<p>Reports of severe medical events have been associated with the intrathecal route of administration (see <span class="Bold"><a href="#AR_G">ADVERSE REACTIONS, Gastrointestinal</a></span> and <span class="Bold"><a href="#AR_NP">Neurologic/Psychiatric</a></span> sections).</p>
<p>Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early mortality (at 2 weeks) and late mortality (at 6 months) in patients with cranial <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> who were determined not to have other clear indications for corticosteroid treatment. High doses of corticosteroids, including CELESTONE SOLUSPAN, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>.</p>
<p>
 
</p>
<p></p>
<p>Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>This product, like many other steroid formulations, is sensitive to heat. Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.</p>
<p>The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
<p>
 
</p>
<p></p>
<p>As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
<p>
 
</p>
<p></p>
<p>Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy. Therefore, in any situation of stress occurring during that period, naturally occurring glucocorticoids (hydrocortisone cortisone), which also have salt-retaining properties, rather than betamethasone, are the appropriate choices as replacement therapy in adrenocortical deficiency states.</p>
<p>
 
</p>
<p></p>
<p>Steroids should be used with caution in active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, since they may increase the risk of a perforation.</p>
<p>Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent.</p>
<p>There is an enhanced effect of corticosteroids in patients with cirrhosis.</p>
<p>
 
</p>
<p></p>
<p>Intra-articular injected corticosteroids may be systemically absorbed.</p>
<p>Appropriate examination of any joint fluid present is necessary to exclude a septic process.</p>
<p>A marked increase in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> accompanied by <span class="product-label-link" type="condition" conceptid="4200520" conceptname="Neck swelling">local swelling</span>, further restriction of joint motion, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> are suggestive of <span class="product-label-link" type="condition" conceptid="80482" conceptname="Suppurative arthritis">septic arthritis</span>. If this complication occurs and the diagnosis of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> is confirmed, appropriate antimicrobial therapy should be instituted.</p>
<p>Injection of a steroid into an infected site is to be avoided. Local injection of a steroid into a previously injected joint is not usually recommended.</p>
<p>Corticosteroid injection into unstable joints is generally not recommended.</p>
<p>Intra-articular injection may result in damage to joint tissues (see <span class="Bold"><a href="#AR_M">ADVERSE REACTIONS, Musculoskeletal</a></span> section).</p>
<p>
 
</p>
<p></p>
<p>Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (ie, decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (ie, postmenopausal women) before initiating corticosteroid therapy.</p>
<p>
 
</p>
<p></p>
<p>Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (eg, <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (eg, pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids.</p>
<p>
 
</p>
<p></p>
<p>Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
<p>
 
</p>
<p></p>
<p>Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Persons who are on corticosteroids should be warned to avoid exposure to <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
<p>
 
</p>
<p></p>
<p>Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.</p>
<p>
 
</p>
<p></p>
<p> When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>
 
</p>
<p></p>
<p>Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.</p>
<p>
 
</p>
<p></p>
<p>Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.</p>
<p>
 
</p>
<p></p>
<p>Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.</p>
<p>
 
</p>
<p></p>
<p>Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.</p>
<p>
 
</p>
<p></p>
<p>Serum concentrations of isoniazid may be decreased.</p>
<p>
 
</p>
<p></p>
<p>Cholestyramine may increase the clearance of corticosteroids.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use.</p>
<p>
 
</p>
<p></p>
<p>Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p>
 
</p>
<p></p>
<p>Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.</p>
<p>
 
</p>
<p></p>
<p>Drugs which induce hepatic microsomal drug-metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.</p>
<p>
 
</p>
<p></p>
<p>Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.</p>
<p>
 
</p>
<p></p>
<p>Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids.</p>
<p>
 
</p>
<p></p>
<p>Corticosteroids may suppress reactions to skin tests.</p>
<p>
 
</p>
<p></p>
<p>Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Route administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see <span class="Bold"><a href="#W_I_V">WARNINGS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, Vaccination</a></span> section).</p>
<p>
 
</p>
<p></p>
<p>No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.</p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients.</p>
<p>
 
</p>
<p></p>
<p>Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>.</p>
<p>
 
</p>
<p></p>
<p>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when corticosteroids are administered to a nursing woman.</p>
<p>
 
</p>
<p></p>
<p>The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month of age). Other indications for pediatric use of corticosteroids, eg, severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.</p>
<p>The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (ie, cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.</p>
<p>
 
</p>
<p></p>
<p>No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and young patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>
 
</p>
<p></p>
<p>Decreased carbohydrate and glucose tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, glucosuria, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, increased requirements for insulin or oral hypoglycemic adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p>
 
</p>
<p></p>
<p>Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</p>
<p>
 
</p>
<p></p>
<p>Negative nitrogen balance due to protein catabolism.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, <span class="product-label-link" type="condition" conceptid="4280820" conceptname="Calcinosis">calcinosis</span> (following intra-articular or intralesional use), Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, postinjection flare (following intra-articular use), <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, psychic disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, and <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> have occurred after intrathecal administration (see <span class="Bold"><a href="#W_N">WARNINGS, Neurologic</a></span> section).</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> associated with periocular injections.</p>
<p>
 
</p>
<p></p>
<p>Abnormal fat deposits, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Benzyl alcohol as a preservative has been associated with a fatal "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Gasping</span> Syndrome" in premature infants and infants of low birth weight. Solutions used for further dilution of this product should be preservative-free when used in the neonate, especially the premature infant. The initial dosage of parenterally administered CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension may vary from 0.25 to 9.0 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.</p>
<p><span class="Italics">It Should Be Emphasized That Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. </span>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.</p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended (see <span class="Bold"><a href="#P_NP">PRECAUTIONS, Neuro-psychiatric</a></span> section).</p>
<p>In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m<span class="Sup">2</span>bsa/day).</p>
<p><span class="Italics">For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids:</span></p>
<table width="75%">
<col align="left" span="1" valign="top" width="50%">
<col align="left" span="1" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">Cortisone, 25</td>
<td align="left">Triamcinolone, 4</td>
</tr>
<tr>
<td align="left">Hydrocortisone, 20</td>
<td align="left">Paramethasone, 2</td>
</tr>
<tr>
<td align="left">Prednisolone, 5</td>
<td align="left">Betamethasone, 0.75</td>
</tr>
<tr>
<td align="left">Prednisone, 5</td>
<td align="left">Dexamethasone, 0.75</td>
</tr>
<tr class="Last">
<td align="left">Methylprednisolone, 4</td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</p>
<p>If coadministration of a local anesthetic is desired, CELESTONE SOLUSPAN Injectable Suspension may be mixed with 1% or 2% lidocaine hydrochloride, using the formulations which do not contain parabens. Similar local anesthetics may also be used. Diluents containing methylparaben, propylparaben, phenol, etc., should be avoided, since these compounds may cause flocculation of the steroid. The required dose of CELESTONE SOLUSPAN Injectable Suspension is first withdrawn from the vial into the syringe. The local anesthetic is then drawn in, and the syringe shaken briefly. <span class="Bold">Do not inject local anesthetics into the vial of CELESTONE SOLUSPAN Injectable Suspension</span>.</p>
<p>
 
</p>
<p></p>
<p>In acute subdeltoid, subacromial, olecranon, and prepatellar <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>, one intrabursal injection of 1.0 mL CELESTONE SOLUSPAN Injectable Suspension can relieve <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and restore full range of movement. Several intrabursal injections of corticosteroids are usually required in recurrent acute <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> and in acute exacerbations of chronic <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span>. Partial relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and some increase in mobility can be expected in both conditions after one or two injections. Chronic <span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> may be treated with reduced dosage once the acute condition is controlled. In <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span> and <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>, three or four local injections at intervals of 1 to 2 weeks between injections are given in most cases. Injections should be made into the affected tendon sheaths rather than into the tendons themselves. In <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglions</span> of joint capsules and tendon sheaths, injection of 0.5 mL directly into the <span class="product-label-link" type="condition" conceptid="72712" conceptname="Synovial cyst">ganglion</span> <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> has produced marked reduction in the size of the lesions.</p>
<p>
 
</p>
<p></p>
<p>Following intra-articular administration of 0.5 to 2.0 mL of CELESTONE SOLUSPAN Injectable Suspension, relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness, and <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> may be experienced. Duration of relief varies widely in both diseases. Intra-articular Injection of CELESTONE SOLUSPAN Injectable Suspension is well tolerated in joints and periarticular tissues. There is virtually no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on injection, and the "secondary flare" that sometimes occurs a few hours after intra-articular injection of corticosteroids has not been reported with CELESTONE SOLUSPAN Injectable Suspension. Using sterile technique, a 20- to 24-gauge needle on an empty syringe is inserted into the synovial cavity and a few drops of synovial fluid are withdrawn to confirm that the needle is in the joint. The aspirating syringe is replaced by a syringe containing CELESTONE SOLUSPAN Injectable Suspension and injection is then made into the joint.</p>
<table width="80%">
<caption><span>Recommended Doses for Intra-articular Injection</span></caption>
<col align="left" span="1" valign="bottom" width="33%">
<col align="left" span="1" valign="bottom" width="34%">
<col align="left" span="1" valign="bottom" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Size of joint</th>
<th align="left" colspan="1">Location</th>
<th align="left" colspan="1">Dose (mL)</th>
</tr>
<tr>
<td align="left">Very large</td>
<td align="left">Hip</td>
<td align="left">1.0-2.0</td>
</tr>
<tr>
<td align="left">Large</td>
<td align="left">Knee, ankle, shoulder</td>
<td align="left">1.0</td>
</tr>
<tr>
<td align="left">Medium</td>
<td align="left">Elbow, wrist</td>
<td align="left">0.5-1.0</td>
</tr>
<tr class="Last">
<td align="left">Small (metacarpophalangeal, interphalangeal)<br>(sternoclavicular)</td>
<td align="left">Hand, chest</td>
<td align="left">0.25-0.5</td>
</tr>
</tbody>
</table>
<p>A portion of the administered dose of CELESTONE SOLUSPAN Injectable Suspension is absorbed systemically following intra-articular injection. In patients being treated concomitantly with oral or parenteral corticosteroids, especially those receiving large doses, the systemic absorption of the drug should be considered in determining intra-articular dosage.</p>
<p>
 
</p>
<p></p>
<p>In intralesional treatment, 0.2 mL/cm<span class="Sup">2</span> of CELESTONE SOLUSPAN Injectable Suspension is injected intradermally (not subcutaneously) using a tuberculin syringe with a 25-gauge, ½-inch needle. Care should be taken to deposit a uniform depot of medication intradermally. A total of no more than 1.0 mL at weekly intervals is recommended.</p>
<p>
 
</p>
<p></p>
<p>A tuberculin syringe with a 25-gauge, ¾-inch needle is suitable for most injections into the foot. The following doses are recommended at intervals of 3 days to a week.</p>
<table width="80%">
<col align="left" span="1" valign="bottom" width="40%">
<col align="left" span="1" valign="bottom" width="60%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">
<br>Diagnosis</th>
<th align="left" colspan="1">CELESTONE SOLUSPAN<br>Injectable Suspension Dose (mL)</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">Bursitis</span><br>  under heloma durum or<br>    heloma molle</td>
<td align="left">
<br><br>0.25-0.5</td>
</tr>
<tr>
<td align="left">  under calcaneal spur</td>
<td align="left">0.5</td>
</tr>
<tr>
<td align="left">  over hallux rigidus or<br>   digiti quinti varus</td>
<td align="left">
<br>0.5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">Tenosynovitis</span>,<br>  <span class="product-label-link" type="condition" conceptid="440822" conceptname="Periostitis">periostitis</span> of cuboid</td>
<td align="left">
<br>0.5</td>
</tr>
<tr class="Last">
<td align="left">Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span></td>
<td align="left">0.5-1.0</td>
</tr>
</tbody>
</table>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>CELESTONE<span class="Sup">®</span> SOLUSPAN<span class="Sup">®</span><a href="#footnote-1" class="Sup">1</a> Injectable Suspension, 5-mL multiple-dose vial; box of one (NDC 0085-0566-05).</p>
<p><span class="Bold">SHAKE WELL BEFORE USING.</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of<br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by: Patheon UK Limited, Covingham, Swindon, Wiltshire, SN3 5BZ, United Kingdom</p>
<p>Copyright © 1969, 2012 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: 05/2012</p>
<p>31550327T</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: CELESTONE SOLUSPAN </p>
<p><br></p>
<p>GENERIC: Betamethasone Acetate and Betamethasone Sodium Phosphate</p>
<p><br></p>
<p>DOSAGE: INJECTION, SUSPENSION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 49349-757-01</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul>
<li>Betamethasone Acetate 3mg in 1mL</li>
<li>Betamethasone Sodium Phosphate 3mg in 1mL</li>
</ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>Benzalkonium Chloride</li>
<li>Edetate Disodium</li>
<li>Sodium Phosphate, Dibasic</li>
<li>Sodium Phosphate, Monobasic</li>
</ul>
<p><br></p>
<p>PACKAGING: 5 mL in 1 VIAL</p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2fb9fb11-d4ab-4c19-b5d1-c0177b3d8ef6&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2fb9fb11-d4ab-4c19-b5d1-c0177b3d8ef6&amp;name=MM3.jpg"></p>
<p>/&gt;
  </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CELESTONE SOLUSPAN 		
					</strong><br><span class="contentTableReg">betamethasone acetate and betamethasone sodium phosphate injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-757(NDC:0085-0566)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Betamethasone Acetate</strong> (BETAMETHASONE) </td>
<td class="formItem">Betamethasone Acetate</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Betamethasone Sodium Phosphate</strong> (BETAMETHASONE) </td>
<td class="formItem">BETAMETHASONE</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzalkonium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Edetate Disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-757-01</td>
<td class="formItem">5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA014602</td>
<td class="formItem">06/10/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>982e3190-cb1d-4fb8-97ed-09d2f66599d4</div>
<div>Set id: 2fb9fb11-d4ab-4c19-b5d1-c0177b3d8ef6</div>
<div>Version: 1</div>
<div>Effective Time: 20130610</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
